Aristea Announces Plans for Phase III Development of AR-YU-69
A Drug for mild Traumatic Brain Injury (Concussion) with Applications in Alzheimer’s Disease Prevention
Sci. Transl. Med. 2, 61rv6 (2010).
“Researching Drugs to Insure Sound Drug Developments”
To Achieve Regulatory Approval
The Drug Must Possess Efficacy and
The Development Must Allow the Drug to Exhibit This Efficacy.